Citations

Clear

2438 citation(s) found for "Ly, Amy".

Impact of Desmopressin ON HemaToma EXPANsion in Patients Presenting to the Emergency Department on Antiplatelet Therapy: DON'T EXPAND Study
Rech, Megan A. , Brown, Caitlin S. , Slocum, Giles W. , Aggarwal, Deep, Ayad, Michael, Delibert, Samantha, Flack, Tara , Guerrero, Luis, Howington, Gavin T. , Koul, Uttara, Laub, Jessica , Malik, Atul, Maynard, Kaylee , Naylor, Ryan M. , Newell, Joshua S, Dee, Elizabeth , Sarangarm, Preeyaporn , Sheldrake, Amy K., Shogren, Sophie L , Treu, Ciarra N, Vantine, Paul, Woolum, Jordan A. , Rech, Megan A , Gilbert, Brian W. , George, Benjamin P. , Koul, Uttara, Malik, Atul, Panos, Nicholas , Ray, Lance , Dee, Elizabeth, Faine, Brett

Mayo Clinic

No container title available | September 3, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4619324/v1 Get It

Abstract Introduction: Current guidelines state the effectiveness of desmopressin to reduce hematoma expansion in antiplatelet-related intracerebral hemorrhage (ICH) is uncertain. This study sought to determine if desmopressin decreased hematoma expansion in ICH patients on antiplatelet agents. Methods: We conducted a multi-center, retrospective propensity-matched cohort study at 11 US emergency departments (ED) that participate in EMPHARM-NET. Adult patients ≥18 years with a primary diagnosis of spontaneous ICH on antiplatelets prior to admission from January 1, 2017 through May 1, 2021 were included. The primary endpoint was good or excellent hemostatic efficacy within the first 24 hours following ICH between patients that did and did not receive desmopressin. Brain imaging was reviewed using 3D-Slicer by blinded expert physicians. Results: Overall, 1408 patients were evaluated for inclusion. A total of 324 patients were included, of which 13.8% (n=45) received desmopressin and 86.1% (n=279) did not. After propensity matching, 35 patients receive desmopressin compared to 140 controls. Baseline hematoma volume (27.6 mL vs. 2.1 mL) and was significantly higher in the desmopressin group. The primary endpoint of good or excellent hemostatic efficacy was similar between groups (74.3% desmopressin group vs. 85% control group, -10.7% [-28.1% to 6.7%]). There was no difference in secondary outcomes. Conclusion: In this multicenter cohort, patients receiving desmopressin had higher baseline intraparenchymal hematoma volume, and did not appear to result in improved hemostatic efficacy relative to the control group. These results suggest against routine administration of desmopressin for antiplatelet-related ICH, though future study in a randomized trial design is necessary.
Burden of illness and treatment attitudes among participants meeting Rome IV criteria for irritable bowel syndrome: A nationwide survey in the United States
Lacy, Brian E. , Xu, Yanqing , Taylor, Douglas C.A., Kosch, Katherine J., Dobrescu, Rachel, Morlock, Amy, Morlock, Robert , Rooker, Ceciel, Rooker, Ceciel

Mayo Clinic

Neurogastroenterology & Motility | September 3, 2024 | Volume: 36 | Issue: 11 | Pages: No page available

10.1111/nmo.14903 | PMID 39223955 Get It

AbstractBackgroundIrritable bowel syndrome (IBS) is a disorder of gut–brain interaction characterized by abdominal pain and altered bowel habits, with patient‐perceived dissatisfaction of treatment symptom control. We assessed disease burden, satisfaction with medication use, and impact on activities, in participants with IBS with constipation (IBS‐C) and diarrhea (IBS‐D).MethodsThis study assessed data from a large, United States survey of adults querying demographics, comorbid conditions, quality of life, medication use, satisfaction with symptom control, and work productivity. Participants were grouped into the IBS‐C or IBS‐D cohort if they met Rome IV criteria, with controls matched 1:1 according to age, sex, race, region, and Charlson Comorbidity Index score. All data were self‐reported.Key ResultsNine hundred and ten participants with IBS‐C and 669 with IBS‐D were matched to controls. The most reported symptoms were abdominal discomfort for IBS‐C and abdominal pain and abdominal discomfort for IBS‐D. Among the IBS‐C and IBS‐D cohorts, 74.2% and 65.9%, respectively, took prescription and/or over‐the‐counter medication for their symptoms. Respondents were more dissatisfied than satisfied with control of their symptoms. Respondents taking prescription medication(s) with or without over‐the‐counter medication(s) reported better symptom control than respondents only taking over‐the‐counter medications (p < 0.001). There was significantly higher mean presenteeism, work productivity loss, and daily activity impairment (p < 0.001 for all) in respondents with IBS compared with controls.Conclusions and InferencesThis study provides insight into respondents' experiences of IBS symptoms, including the impact on daily activity, as well as satisfaction with control of symptoms and prescription and over‐the‐counter medications.
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial
Desai, Milind Y. , Okushi, Yuichiro , Gaballa, Andrew , Wang, Qiuqing, Geske, Jeffrey B. , Owens, Anjali , Saberi, Sara , Wang, Andrew , Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Naidu, Srihari S. , Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Masri, Ahmad , Zenker, M., Wheeler, M., Bach, R., Rader, F., Bajona, Pietro, Owens, Anjali T , Cremer, Paul C , Sherrid, Mark , Lakdawala, Neal K , Tower-Rader, Albree , Naidu, Srihari S , Sehnert, Amy J , Nissen, Steven E , Popovic, Zoran B , Geske, Jeffrey B , Saberi, Sara , Wang, Andrew , Sherrid, Mark V. , Fermin, David , Stendahl, John C. , Orford, J.

Mayo Clinic

Circulation: Cardiovascular Imaging | September 2, 2024 | Volume: 17 | Issue: 9 | Pages: No page available

10.1161/circimaging.124.017185 | PMID 39221824 Get It

BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy, VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) demonstrated that mavacamten reduces the need for septal reduction therapy with sustained improvement in left ventricular (LV) outflow tract gradients and symptoms. Global longitudinal strain (GLS), a measure of regional myocardial function, is a more sensitive marker of systolic function. In VALOR-HCM, we assessed serial changes in LV and right ventricular (RV) strain. METHODS: VALOR-HCM included 112 patients with symptomatic obstructive hypertrophic cardiomyopathy (mean, 60 years; 51% male; LV ejection fraction, 68%). Patients assigned to mavacamten at baseline continued the drug for 56 weeks (n=56) and those assigned to placebo (n=52) transitioned to mavacamten from weeks 16 to 56 (40-week exposure). LV-GLS and RV-GLS assessment was performed using a vendor-neutral software. Non-foreshortened apical (4-, 3-, and 2-chamber) views were used to obtain peak LV-GLS. RV focused 4-chamber view was used to calculate RV 4-chamber and free wall strain. A more negative strain value is favorable. RESULTS: At baseline, the mean LV-GLS, RV 4-chamber, and free wall strain values were −14.7%, −22.2%, and −16.8%, respectively (all worse than reported normal means). In the total study sample, LV-GLS significantly improved from baseline to week 56 ( P =0.02). Twelve patients had transient reduction in LV ejection fraction (<50%) requiring temporary drug interruption (including 3 permanent discontinuations). The LV-GLS in this subgroup was worse at baseline versus total study population (−11.4%), with no significant worsening from baseline through week 56 ( P =0.64). Both free wall and 4-chamber RV-GLS remained unchanged from baseline to week 56 ( P =0.62 and P =0.56, respectively). CONCLUSIONS: In VALOR-HCM, treatment with mavacamten improved LV-GLS from baseline through week 56 (with no significant worsening of LV-GLS in patients with a reduction in LV ejection fraction ≤50%), suggesting a favorable long-term impact on regional LV systolic function. Additionally, there was no detrimental impact on RV systolic function. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.
Digital Otoscopy With Computer‐Aided Composite Image Generation: Impact on the Correct Diagnosis, Confidence, and Time
Çamalan, Seda , Langefeld, Carl D. , Zinnia, Amy , McKee, Brigham, Carlson, Matthew L. , Deep, Nicholas L. , Harris, Michael S. , Kaul, Vivian F. , Lindquist, Nathan R. , Mattingly, Jameson K. , Shah, Jay , Zhan, Kevin Y. , Harris, Michael S , Jan, Taha Adnan , Gürcan, Metin N. , Moberly, Aaron C.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | September 2, 2024 | Volume: 172 | Issue: 1 | Pages: 152-161

10.1002/ohn.965 | PMID 39221462 Get It

AbstractObjectiveThis study investigated the comparative performance of ear, nose, and throat (ENT) physicians in correctly detecting ear abnormalities when reviewing digital otoscopy imaging using 3 different visualization methods, including computer‐assisted composite images called “SelectStitch,” single video frame “Still” images, and video clips. The study also explored clinicians' diagnostic confidence levels and the time to make a diagnosis.Study DesignClinician diagnostic reader study.SettingOnline diagnostic survey of ENT physicians.MethodsNine ENT physicians reviewed digital otoscopy examinations from 86 ears with various diagnoses (normal, perforation, retraction, middle ear effusion, tympanosclerosis). Otoscopy examinations used artificial‐intelligence (AI)‐based computer‐aided composite image generation from a video clip (SelectStitch), manually selected best still frame from a video clip (Still), or the entire video clip. Statistical analyses included comparisons of ability to detect correct diagnosis, confidence levels, and diagnosis times.ResultsThe ENT physicians' ability to detect ear abnormalities (33.2%‐68.7%) varied depending on the pathologies. SelectStitch and Still images were not statistically different in detecting abnormalities (P > .50), but both were different from Video (P < .01). However, the performance improvement observed with Videos came at the cost of significantly longer time to determining the diagnosis. The level of confidence in the diagnosis was positively associated with correct diagnoses, but varied by particular pathology.ConclusionThis study explores the potential of computer‐assisted techniques like SelectStitch in enhancing otoscopic diagnoses and time‐saving, which could benefit telemedicine settings. Comparable performance between computer‐generated and manually selected images suggests the potential of AI algorithms for otoscopy applications.
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Zayac, Adam , Bock, Allison M. , Nowakowski, Grzegorz S. , Ayers, Emily C. , Girton, Mark , Hu, Marie , Beckman, Amy , Li, Shaoying , Chang, Julie E , Sandoval‐Sus, Jose , Ansari‐Lari, M. Ali, Kothari, Shalin , Kress, Anna, Xu, Mina L. , Torka, Pallawi , Smith, Stephen D. , Naresh, Kikkeri N. , Karimi, Yasmin , Evens, Andrew M. , Naik, Seema , Kamdar, Manali , Haverkos, Bradley M. , Rubinstein, P , Chaudhry, Amina, Epperla, Narendranath , Zayac, Adam S , Bock, Allison M , Ayers, Emily C , Girton, Mark , Hu, Marie , Li, Shaoying , Medeiros, L Jeffrey , Chang, Julie E , Torka, Pallawi , Smith, Stephen D , Karimi, Yasmin H , Bond, David A , Naik, Seema G , Haverkos, Bradley M , Karmali, Reem , Farooq, Umar , Vose, Julie , Rubinstein, Paul G , Olszewski, Adam J , Evens, Andrew M , Naresh, Kikkeri N , Kamdar, Manali , Epperla, Narendranath , Landsburg, Daniel J. , Medeiros, L. Jeffrey , Kurt, Habibe , Sundaram, Suchitra , Bond, David A. , Karmali, Reem , Vose, Julie M. , Chaudhry, Amina, Olszewski, Adam J.

Mayo Clinic

Blood Advances | August 27, 2024 | Volume: 8 | Issue: 20 | Pages: 5355-5364

10.1182/bloodadvances.2024013791 | PMID 39189932 Get It

Abstract Little is known about the central nervous system (CNS) risk in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS). Hence, we sought to describe the rates of baseline CNS involvement, risk of CNS recurrence after primary therapy, and management strategies in HGBL NOS. In this multicenter retrospective study, we included 160 adults with newly diagnosed HGBL NOS treated between 2016 and 2021 at 20 US institutions. Eleven patients (7%) had baseline CNS involvement at diagnosis (leptomeningeal = 6, parenchymal = 4, and both = 1). Baseline CNS involvement was significantly associated only with MYC rearrangement (OR = 3.5) and testicular (in men) or female pelvic (in women) involvement (OR = 8.1). There was no significant difference in survival outcomes between patients with HGBL NOS with (median PFS = 4 years) or without (median PFS = 2.4 years) baseline CNS involvement (P = 0.45). The cumulative incidence of CNS recurrence at 3 years was 11%. Patients with baseline CNS involvement were at the highest risk (48.5% vs 8% for those without baseline CNS involvement) and were excluded from the risk factors analysis for CNS recurrence. The risk for CNS recurrence was significantly associated with blood or bone marrow involvement, CD5 expression, non–germinal center B-cell subtype, and “dual-expresser lymphoma” phenotype, however, high CNS IPI was not. The prognosis of relapsed HGBL NOS was poor, regardless of whether recurrence was systemic or limited to the CNS, and with currently available salvage strategies, including autologous transplantation and chimeric antigen receptor T-cell modalities, almost all patients with CNS recurrence ultimately succumbed to their disease.
RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2 -Mutated Clonal Hematopoiesis
Ben-Crentsil, Nana Adjoa , Ismail, Wazim Mohammed , Newman, Hannah , Quintana, Ariel , Binder, Moritz , Kruer, Traci , Neupane, Surendra , Ferrall‐Fairbanks, Meghan C. , Fernandez, Jenna , Finke, Christy M. , Ibrahim, Mohammed L. , McGraw, Kathy L. , Wysota, Michael , Aldrich, Amy L. , Letson, Christopher T. , Traina, Joshua , McLemore, Amy F. , Droin, Nathalie , Sallman, David A. , Beg, Amer A. , Ma, Li , Gaspar‐Maia, Alexandre , Patnaik, Mrinal M. , Padron, Eric , Mohammed Ismail, Wazim , Balasis, Maria , Newman, Hannah , Quintana, Ariel , Binder, Moritz , Kruer, Traci , Neupane, Surendra , Ferrall-Fairbanks, Meghan C , Fernandez, Jenna , Lasho, Terra L , Finke, Christy M , Ibrahim, Mohammed L , McGraw, Kathy L , Wysota, Michael , Aldrich, Amy L , Ryder, Christopher B , Letson, Christopher T , Traina, Joshua , McLemore, Amy F , Droin, Nathalie , Shastri, Aditi , Yun, Seongseok , Solary, Eric , Sallman, David A , Beg, Amer A , Ma, Li , Gaspar-Maia, Alexandre , Patnaik, Mrinal , Padron, Eric , Balasis, Maria E. , Lasho, Terra L. , Yun, Seongseok , Solary, Éric

Mayo Clinic

Cancer Discovery | August 27, 2024 | Volume: 14 | Issue: 12 | Pages: 2509-2531

10.1158/2159-8290.cd-24-0093 | PMID 39189614 Get It

Abstract TET2 mutations (mTET2) are common genetic events in myeloid malignancies and clonal hematopoiesis. These mutations arise in the founding clone and are implicated in many clinical sequelae associated with oncogenic feedforward inflammatory circuits. However, the direct downstream effector of mTET2 responsible for the potentiation of these inflammatory circuits is unknown. To address this, we performed scRNA-seq and scATAC-seq in patients with COVID-19 with and without TET2-mutated clonal hematopoiesis reasoning that inflammation from COVID-19 may highlight critical downstream transcriptional targets of mTET2. Using this approach, we identified metastasis-associated lung adenoma transcript 1 (MALAT1), a therapeutically tractable lncRNA, as a central downstream effector of mTET2 that is both necessary and sufficient to induce the oncogenic proinflammatory features of mTET2 in vivo. We also elucidate the mechanism by which mTET2 upregulate MALAT1 and describe an interaction between MALAT1 and p65, which leads to RNA “shielding” from protein phosphatase 2A dephosphorylation, thus preventing resolution of inflammatory signaling. Significance: This work identifies MALAT1 as a requisite downstream effector of oncogenic feedforward inflammatory circuits necessary for the development of TET2-mutated CH and fulminant myeloid malignancy. We elucidate a novel mechanism by which MALAT1 “shields” p65 from dephosphorylation to potentiate this circuit and nominate MALAT1 inhibition as a future therapeutic strategy.
Repetitive Head Impacts and Perivascular Space Volume in Former American Football Players
Jung, Leonard , Wiegand, Tim L. T. , Tuz‐Zahra, Fatima , Iliff, Jeffrey J. , Piantino, Juan , Arciniega, Hector , Kim, Cara L., Pankatz, Lara, Lin, Alexander , Alosco, Michael L. , Daneshvar, Daniel H. , Pasternak, Ofer , Coleman, Michael J. , Bernick, Charles , Balcer, Laura J. , Reiman, Eric M. , Shenton, Martha E., Protas, Hillary , Boker, Conni, Kowall, Neil W. , Otis, James , Weller, Jason , Simkin, Irene, Andino, Alondra, Diamond, Courtney , Fagle, Tessa, Haller, Olivia, Hung, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen , Nanna, Mary, Platt, Taylor, Pulukuri, Sury, Rica, Fiona, Sestak, Madison, Annis, Douglas S. , Dixon, Dianne B., Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Martin, Brett, Palmisano, Joseph , Pine, Brittany, Fitzsimmons, Jennifer, Breedlove, Katherine M. , Coello, Eduardo , Liao, Hujiun, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah J. , Ritter, Aaron, Sabbagh, Marwan N. , Cruz, Raelynn de la, Durant, Jan, Golceker, Moragn, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Falk, Bryce W., Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Kirov, Ivian, Marmar, Charles R. , Hasanaj, Lisene, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan , Martin, Sammie, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth A. , Marcus, Daniel S. , Gurney, Jenny , Johnson, Keith A. , Greenwald, Richard M., Shenton, Martha E. , Daneshvar, Daniel H , Shenton, Martha E , Tripodis, Yorghos , Bouix, Sylvain , Mez, Jesse , Sepehrband, Farshid , Rathi, Yogesh , Adler, Charles H. , Cummings, Jeffrey L. , Stern, Robert A. , Koerte, Inga K , Su, Yi , Chen, Kewei , Boker, Connie, Au, Rhoda , Cantu, Robert C. , Farrer, Lindsay A. , Helm, Robert H. , Mercier, Gustavo , Conneely, Shannon E. , Diamond, Courtney, Pulukuri, Surya Vamsi , McClean, Michael D , Annis, Douglas, Chaisson, Christine E. , Finney, Carolyn, Lü, Jun , Ojo, Emmanuel, Ramachandran, Janani , Bonke, Elena M. , Breedlove, Katherine , Miller, Jason Rafe , II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Wethe, Jennifer V. , Falk, Bryce, Montague, Michelle, Barr, William , Goldberg, Judith D. , Wısnıewskı, Thomas , Lui, Yvonne W. , George, Allan, Riley, Edward P.

Mayo Clinic

JAMA Network Open | August 26, 2024 | Volume: 7 | Issue: 8 | Pages: e2428687

10.1001/jamanetworkopen.2024.28687 | PMID 39186275 Get It

ImportanceExposure to repetitive head impacts (RHI) is associated with increased risk for neurodegeneration. Accumulation of toxic proteins due to impaired brain clearance is suspected to play a role.ObjectiveTo investigate whether perivascular space (PVS) volume is associated with lifetime exposure to RHI in individuals at risk for RHI-associated neurodegeneration.Design, Setting, and ParticipantsThis cross-sectional study was part of the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project, a 7-year multicenter study consisting of 4 US study sites. Data were collected from September 2016 to February 2020 and analyses were performed between May 2021 and October 2023. After controlling for magnetic resonance image (MRI) and processing quality, former American football players and unexposed asymptomatic control participants were included in analyses.ExposurePrior exposure to RHI while participating in American football was estimated using the 3 cumulative head impact indices (CHII-G, linear acceleration; CHII-R, rotational acceleration; and CHII, number of head impacts).Main Outcomes and MeasuresIndividual PVS volume was calculated in the white matter of structural MRI. Cognitive impairment was based on neuropsychological assessment. Linear regression models were used to assess associations of PVS volume with neuropsychological assessments in former American football players. All analyses were adjusted for confounders associated with PVS volume.ResultsAnalyses included 224 participants (median [IQR] age, 57 [51-65] years), with 170 male former football players (114 former professional athletes, 56 former collegiate athletes) and 54 male unexposed control participants. Former football players had larger PVS volume compared with the unexposed group (mean difference, 0.28 [95% CI, 0.00-0.56]; P = .05). Within the football group, PVS volume was associated with higher CHII-R (β = 2.71 × 10−8 [95% CI, 0.50 × 10−8 to 4.93 × 10−8]; P = .03) and CHII-G (β = 2.24 × 10−6 [95% CI, 0.35 × 10−6 to 4.13 × 10−6]; P = .03). Larger PVS volume was also associated with worse performance on cognitive functioning in former American football players (β = −0.74 [95% CI, −1.35 to −0.13]; P = .04).Conclusions and RelevanceThese findings suggest that impaired perivascular brain clearance, as indicated by larger PVS volume, may contribute to the association observed between RHI exposure and neurodegeneration.
Treatment for chronic idiopathic constipation: Use and satisfaction from a nationwide survey of US participants
Lacy, Brian E. , Xu, Yanqing , Taylor, Douglas C.A., Kosch, Katherine J., Dobrescu, Rachel, Morlock, Amy, Morlock, Robert , Rooker, Ceciel, Rooker, Ceciel

Mayo Clinic

Neurogastroenterology & Motility | August 19, 2024 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/nmo.14885 | PMID 39155456 Get It

AbstractBackgroundChronic idiopathic constipation (CIC) is a disorder of gut–brain interaction characterized by a variety of bowel movement‐related and abdominal symptoms. A greater understanding of medication use and satisfaction with symptom control may provide insights to optimize patient care. Therefore, we explored these aspects of the disorder in adults with CIC.MethodsThis study assessed data collected from a large nationwide survey of adult participants in the United States, querying demographics, clinical characteristics, and comorbid conditions, as well as medication use, care‐seeking behaviors, and satisfaction with symptom control. Participants were grouped into the CIC cohort if they met Rome IV criteria, with controls matched 1:1 according to age, sex, race, region, and Charlson Comorbidity Index score. All data were self‐reported.Key ResultsTwo thousand five hundred and thirty‐three participants with CIC were matched 1:1 to controls. In the CIC cohort, abdominal pain was the most reported symptom leading to medication use: 15.9% of respondents were receiving a prescription medication in addition to an over‐the‐counter medication, while 26.3% were taking neither. In addition, only one‐third were satisfied with the control of their symptoms; however, satisfaction was significantly higher in respondents taking a prescription medication (p < 0.001). The proportion of reported comorbidities was significantly higher in the CIC cohort versus the control cohort, with chronic pain, anxiety, and depression among the highest (p < 0.001 for all).Conclusions and InferencesThis study emphasizes the need for better communication regarding prescription medications and their benefits, with the goal of further improving CIC patients' overall symptoms.
The headache research priorities: Research goals from the American Headache Society and an international multistakeholder expert group
Pradhan, Amynah , Brin, Mitchell F. , Rosen, Howard J. , Lalvani, Nim, Ashina, Messoud , Phu, Thien , Digre, Kathleen B. , Russo, Andrew F. , Buse, Dawn C. , Tassorelli, Cristina, Goadsby, Peter J., Robertson, Carrie E. , Ezzati, Ali , Pradhan, Amynah A , Charles, Andrew , Ashina, Messoud , Gelfand, Amy A , Dodick, David W , Lipton, R.B. , Robertson, Carrie E , Schwedt, Todd J. , Oshinsky, Michael L. , Charles, Andrew , Burstein, Rami , Gelfand, Amy A. , Dodick, David W. , Pozo‐Rosich, Patricia , Lipton, Richard B. , Ailani, Jessica , Szperka, Christina L. , Charleston, Larry , Powers, Scott W. , Tassorelli, Cristina

Mayo Clinic

Headache: The Journal of Head and Face Pain | August 16, 2024 | Volume: 64 | Issue: 8 | Pages: 912-930

10.1111/head.14797 | PMID 39149968 Get It

Abstract Objective To identify and disseminate research priorities for the headache field that should be areas of research focus during the next 10 years. Background Establishing research priorities helps focus and synergize the work of headache investigators, allowing them to reach the most important research goals more efficiently and completely. Methods The Headache Research Priorities organizing and executive committees and working group chairs led a multistakeholder and international group of experts to develop headache research priorities. The research priorities were developed and reviewed by clinicians, scientists, people with headache, representatives from headache organizations, health‐care industry representatives, and the public. Priorities were revised and finalized after receiving feedback from members of the research priorities working groups and after a public comment period. Results Twenty‐five research priorities across eight categories were identified: human models, animal models, pathophysiology, diagnosis and management, treatment, inequities and disparities, research workforce development, and quality of life. The priorities address research models and methods, development and optimization of outcome measures and endpoints, pain and non‐pain symptoms of primary and secondary headaches, investigations into mechanisms underlying headache attacks and chronification of headache disorders, treatment optimization, research workforce recruitment, development, expansion, and support, and inequities and disparities in the headache field. The priorities are focused enough that they help to guide headache research and broad enough that they are widely applicable to multiple headache types and various research methods. Conclusions These research priorities serve as guidance for headache investigators when planning their research studies and as benchmarks by which the headache field can measure its progress over time. These priorities will need updating as research goals are met and new priorities arise.
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes
Jacobs, Jeremy W. , Stanek, C , Symeonidis, Argiris , Shih, Andrew W. , Gavriilaki, Eleni , Pavenski, Katerina , Moorehead, Amy , Mingot‐Castellano, María Eva , Daou, Laetitia , Arnold, Donald M. , Henrie, Ryan , Smith, Tyler , Sreenivasan, Gayatri , Siniard, Rance C. , Wallace, Lisa R., Duque, Miriam Andrea, Wu, Yanyun , Harrington, Thomas J., Byrnes, Diana M. , Bitsani, Aikaterini , Davis, Amanda K. , Robinson, Danielle H., Eichbaum, Quentin , Kaiafa, Georgia , Klapper, Ellen, Klein, Monica S., Kotsiou, Nikolaos , Lalayanni, Chrysavgi , Mandala, Evdokia , Alkhateb, Rahaf, Fortuny, Lisandro, Mellios, Zois, Papalexandri, Apostolia, Parsons, Meredith G , Wellard, Cameron , Jia, Shiyang , Powers, Amy, Webb, Christopher B. , Yates, Sean G. , Bouzid, Raïda , Coppo, Paul, Bloch, Evan M. , Adkins, Brian D. , Stanek, Caroline G , Booth, Garrett , Symeonidis, Argiris , Shih, Andrew W , Gavriilaki, Eleni , Moorehead, Amy , Peyvandi, Flora , Mancini, Ilaria , Raval, Jay S , Mingot-Castellano, Maria Eva , Crowe, Elizabeth P , Arnold, Donald M , Yamada, Chisa , Kotsiou, Nikolaos , Aldarweesh, Fatima , Schlueter, Annette J , Tormey, Christopher A , Wood, Erica M , Wheeler, Allison P , Yates, Sean G , Bloch, Evan M , Adkins, Brian David , Jacobs, Jeremy W , Parsons, Meredith G , Booth, Garrett S. , Allen, Elizabeth S. , Grossman, Brenda J. , Pavenski, Katerina , Peyvandi, Flora , Agosti, Pasquale , Stephens, Laura D. , Raval, Jay S. , Pai, Menaka , Marques, Marisa B. , Yamada, Chisa , Robinson, Danielle H. , Villalba, Cristina A. Figueroa , Juskewitch, Justin E. , Kapsali, Eleni , Perez-Alvarez, Ingrid , Aldarweesh, Fatima , Schlueter, Annette J. , Tormey, Christopher A. , Wheeler, Allison P. , Coppo, Paul

Mayo Clinic

American Journal of Hematology | August 13, 2024 | Volume: 99 | Issue: 11 | Pages: 2063-2074

10.1002/ajh.27458 | PMID 39136282 Get It

AbstractPrior studies have suggested that immune thrombotic thrombocytopenic purpura (iTTP) may display seasonal variation; however, methodologic limitations and sample sizes have diminished the ability to perform a rigorous assessment. This 5‐year retrospective study assessed the epidemiology of iTTP and determined whether it displays a seasonal pattern. Patients with both initial and relapsed iTTP (defined as a disintegrin and metalloprotease with thrombospondin type motifs 13 activity <10%) from 24 tertiary centers in Australia, Canada, France, Greece, Italy, Spain, and the US were included. Seasons were defined as: Northern Hemisphere—winter (December–February); spring (March–May); summer (June–August); autumn (September–November) and Southern Hemisphere—winter (June–August); spring (September–November); summer (December–February); autumn (March–May). Additional outcomes included the mean temperature in months with and without an iTTP episode at each site. A total of 583 patients experienced 719 iTTP episodes. The observed proportion of iTTP episodes during the winter was significantly greater than expected if equally distributed across seasons (28.5%, 205/719, 25.3%–31.9%; p = .03). Distance from the equator and mean temperature deviation both positively correlated with the proportion of iTTP episodes during winter. Acute iTTP episodes were associated with the winter season and colder temperatures, with a second peak during summer. Occurrence during winter was most pronounced at sites further from the equator and/or with greater annual temperature deviations. Understanding the etiologies underlying seasonal patterns of disease may assist in discovery and development of future preventative therapies and inform models for resource utilization.